Sheen P C, Lee K T, Chen H Y, Chen J S, Ker C G
Department of Surgery, Kaohsiung Medical College Hospital, Taiwan.
Int Surg. 1996 Jul-Sep;81(3):280-3.
We evaluated in retrospect the applicability of conservative hepatic resection for hepatocellular carcinoma (HCC) of cirrhotic patients. Eighty (14.6%) of 548 patients with HCC underwent liver resection over a period of 10 years in this hospital. They were divided into two groups according to surgical procedures. In group I, 22 patients underwent major hepatic resection, and in group II, 58 patients underwent conservative liver resection. The operative mortality for patients in group I was 13.6% while it was 3.5% for those in group II. The difference was significant (p<0.05). The five-year survival rate was 22% for patients in group I, while it was 21% for group II patients. The rate of HCC recurrence was 47.4% for group I patients while it was 57.1% for group II patients. The difference was not significant. The tumor-free survival rates at 6-, 12-, 24- and 36-months were 80%, 75%, 55% and 55% respectively for patients in group I, while they were 50%, 42.5%, 42.5% and 42.5% for patients in group II. It suggested that conservative liver resection was associated with early recurrence of HCC. But the difference of mean tumor-free survival time is not significant (35.82+/-5.47 vs 38.63+/-8.05 months, p>0.05). Using Cox's regression analysis, the presence of Child's B was identified as an independent adverse prognostic factor (p=0.000) for long-term survival. The factors associated with poor tumor-free survival rate were Child's classification (p=0.008), metastasis (p=0.021), liver cirrhosis (p=0.039) and tumor size (p=0.054). By evaluating the operative mortality, long-term survival rate, prognostic factors for cumulative survival time and tumor-free survival time, it suggests that conservative liver resection can be selectively used to treat HCC associated with liver cirrhosis.
我们回顾性评估了保守性肝切除术在肝硬化患者肝细胞癌(HCC)治疗中的适用性。在本院10年期间,548例HCC患者中有80例(14.6%)接受了肝切除术。根据手术方式将他们分为两组。第一组22例患者接受了大肝切除术,第二组58例患者接受了保守性肝切除术。第一组患者的手术死亡率为13.6%,而第二组为3.5%。差异具有显著性(p<0.05)。第一组患者的5年生存率为22%,第二组患者为21%。第一组患者的HCC复发率为47.4%,第二组为57.1%。差异无显著性。第一组患者在6个月、12个月、24个月和36个月时的无瘤生存率分别为80%、75%、55%和55%,而第二组患者分别为50%、42.5%、42.5%和42.5%。这表明保守性肝切除术与HCC的早期复发有关。但平均无瘤生存时间的差异无显著性(35.82±5.47 vs 38.63±8.05个月,p>0.05)。采用Cox回归分析,发现Child's B级是长期生存的独立不良预后因素(p=0.000)。与无瘤生存率低相关的因素有Child's分级(p=0.008)、转移(p=0.021)、肝硬化(p=0.039)和肿瘤大小(p=0.054)。通过评估手术死亡率、长期生存率、累积生存时间和无瘤生存时间的预后因素,表明保守性肝切除术可选择性用于治疗与肝硬化相关的HCC。